Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours

NCT05021120 is registered in ClinicalTrials.gov with Akesobio Australia Pty Ltd as lead sponsor.

NCT NCT05021120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05021120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours
Lead sponsor
Akesobio Australia Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
October 12, 2021
Completion date
April 1, 2025
Enrollment
67 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumours